High-Performance Antibody & Antigen Portfolios for IVD Assays
November 4, 2026
This white paper introduces a curated portfolio of high-purity antibody and antigen raw materials sourced from leading global manufacturing partners, featuring clinical validation data across major diagnostic platforms and reliable bulk supply capabilities for IVD assay manufacturers.
- IVD R&D Scientists, Assay Developers, and Procurement Managers
- Professionals seeking validated raw materials optimized for CLIA, POCT (Lateral Flow), or Turbidimetric Immunoassays
- Diagnostic manufacturers looking for a reliable global supply partner covering a broad spectrum of clinical applications
2. Key Highlights of This White Paper
Extensive Portfolio Covering 20+ Clinical Disease Categories
Offers a curated selection of high-purity antibodies and antigens engineered for diverse assay formats and detection systems.
- Antibodies: Monoclonal Antibodies / Polyclonal Antibodies / Recombinant Antibodies
- Antigens: Native Antigens / Recombinant Antigens
- Core Disease Coverage: 20+ major clinical fields, including Infectious Diseases, Cardiac Markers, Alzheimer’s Disease, Tumor Markers, Autoimmune, Allergy, Metabolic Disorders, and Hormones
Clinical Validation & Technical Performance Data
Explore detailed evaluation reports inside the PDF, featuring:
- Limits of Detection & Quantitation (LOD / LOQ) for high-sensitivity assays
- Clinical Correlation Studies (R²) against global benchmark reagents and LC-MS/MS standards
- Accelerated Stability & Lot-to-Lot Reproducibility performance data
Certified Quality & Supply Reliability via Partner Network
Features raw material solutions backed by ISO 13485-certified manufacturing partners, offering:
- Advanced Raw Material Screening & Platform Matching
- High-Volume, Multi-Site Bulk Supply Capabilities
- Global Quality Standards & Regulatory Compliance
Please complete the form below to receive immediate access to the full PDF white paper.